title: Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.
abstract: OBJECTIVE
  This study evaluated the efficacy and safety of the alpha(1A)/alpha(1D) subtype-selective blocker tamsulosin for the increasingly common treatment of benign prostatic hyperplasia (BPH) in the primary care setting.
  
  
  METHODS
  A total of 493 men (age > or = 45 years), 99.6% of whom had moderate or severe BPH at baseline, were given tamsulosin 0.4 mg/day in a multicenter, open-label study conducted over 45 days by 42 primary care physicians and two urologists.
  
  
  RESULTS
  Mean American Urological Association (AUA) Symptom Score decreased by 7.5 from a baseline of 20.0 on day 4, representing a 37.5% improvement over baseline (p < 0.001). AUA Obstructive and Irritative Scores declined significantly by day 4 (-4.7 and -2.7, respectively), as did AUA Bother Score (-5.4, p < 0.001) and mean BPH Impact Score (-2.5, p < 0.001). The Investigator's Global Assessment showed slight or greater improvement in 77.2% of patients (13.7% markedly improved). Effects were maintained from day 4 through day 45.
  
  
  CONCLUSIONS
  Overall, patients treated with tamsulosin in a primary care setting experienced rapid, significant improvement in their signs and symptoms of BPH, based upon the change in the AUA Symptom Score. Tamsulosin was well tolerated; no new safety concerns were observed. Tamsulosin was not associated with significant effects on blood pressure or first-dose hypotension.
authors: Department of Internal Medicine, University of South Florida, Tampa, 33606, USA. mflann5555@aol.com
authors: Michael T
authors: MT
authors: Flannery
authors: Joe
authors: J
authors: Ramsdell
authors: Alan
authors: A
authors: Ranhosky
authors: Giora
authors: G
authors: Davidai
authors: Gary
authors: G
authors: Ruoff